Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 2
1981 3
1982 2
1984 2
1985 1
1987 2
1988 3
1990 4
1991 2
1992 3
1993 4
1994 6
1995 4
1996 2
1997 2
1998 3
1999 8
2000 7
2001 4
2002 2
2003 10
2004 11
2005 7
2006 14
2007 16
2008 18
2009 12
2010 14
2011 18
2012 21
2013 13
2014 29
2015 24
2016 20
2017 26
2018 26
2019 33
2020 82
2021 75
2022 65
2023 72
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

628 results

Results by year

Filters applied: . Clear all
Page 1
Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?
Avancini A, Sartori G, Gkountakos A, Casali M, Trestini I, Tregnago D, Bria E, Jones LW, Milella M, Lanza M, Pilotto S. Avancini A, et al. Among authors: milella m. Oncologist. 2020 Mar;25(3):e555-e569. doi: 10.1634/theoncologist.2019-0463. Epub 2019 Nov 26. Oncologist. 2020. PMID: 32162811 Free PMC article. Review.
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer.
Belluomini L, Avancini A, Sposito M, Milella M, Rossi A, Pilotto S. Belluomini L, et al. Among authors: milella m. Expert Opin Biol Ther. 2023 Jul-Dec;23(11):1077-1087. doi: 10.1080/14712598.2023.2198087. Epub 2023 Apr 3. Expert Opin Biol Ther. 2023. PMID: 36995069 Review.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Rosell R, et al. Among authors: milella m. Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26. Lancet Oncol. 2012. PMID: 22285168 Clinical Trial.
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. McCubrey JA, et al. Among authors: milella m. Biochim Biophys Acta. 2007 Aug;1773(8):1263-84. doi: 10.1016/j.bbamcr.2006.10.001. Epub 2006 Oct 7. Biochim Biophys Acta. 2007. PMID: 17126425 Free PMC article. Review.
Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells.
Simbolo M, Silvestris N, Malleo G, Mafficini A, Maggino L, Cocomazzi A, Veghini L, Mombello A, Pezzini F, Sereni E, Martelli FM, Gkountakos A, Ciaparrone C, Piredda ML, Ingravallo G, Paolino G, Nappo F, Rapposelli IG, Frassinetti L, Saragoni L, Lonardi S, Pea A, Paiella S, Fassan M, Brunetti O, Cingarlini S, Salvia R, Milella M, Corbo V, Lawlor RT, Scarpa A, Luchini C. Simbolo M, et al. Among authors: milella m. Mod Pathol. 2023 Sep;36(9):100251. doi: 10.1016/j.modpat.2023.100251. Epub 2023 Jun 22. Mod Pathol. 2023. PMID: 37355152 Free article.
Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories.
Sposito M, Belluomini L, Pontolillo L, Tregnago D, Trestini I, Insolda J, Avancini A, Milella M, Bria E, Carbognin L, Pilotto S. Sposito M, et al. Among authors: milella m. J Pers Med. 2023 Sep 22;13(10):1427. doi: 10.3390/jpm13101427. J Pers Med. 2023. PMID: 37888038 Free PMC article. Review.
Cancer Stem Cells in Renal Cell Carcinoma: Origins and Biomarkers.
Lasorsa F, Rutigliano M, Milella M, Ferro M, Pandolfo SD, Crocetto F, Autorino R, Battaglia M, Ditonno P, Lucarelli G. Lasorsa F, et al. Among authors: milella m. Int J Mol Sci. 2023 Aug 24;24(17):13179. doi: 10.3390/ijms241713179. Int J Mol Sci. 2023. PMID: 37685983 Free PMC article. Review.
Heroin and its metabolites: relevance to heroin use disorder.
Milella MS, D'Ottavio G, De Pirro S, Barra M, Caprioli D, Badiani A. Milella MS, et al. Transl Psychiatry. 2023 Apr 8;13(1):120. doi: 10.1038/s41398-023-02406-5. Transl Psychiatry. 2023. PMID: 37031205 Free PMC article. Review.
628 results